Stock Quotes in this Article: GERN, OXBT, CCXI, PBMD, CANF

DELAFIELD, Wis. (Stockpickr) -- At Stockpickr, we track daily portfolios of stocks that are the biggest percentage gainers and the biggest percentage losers.

>>5 Big Trades to Take This Year

Stocks that are making large moves like these are favorites among short-term traders because they can jump into these names and try to capture some of that massive volatility. Stocks that are making big-percentage moves either up or down are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining technical indicators with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

>>5 Stocks Insiders Love Right Now

With that in mind, let's take a closer look at a several stocks under $10 that are making large moves to the upside.

Oxygen Biotherapeutics

Oxygen Biotherapeutics (OXBT), a development-stage company, engages in developing biotechnology products that deliver oxygen to target tissues in the body. This stock closed up 9% to $5.76 in Thursday's trading session.

Thursday's Range: $5.18-$6.07

52-Week Range: $1.19-$22.00

Thursday's Volume: 1.28 million

Three-Month Average Volume: 147,898

>>5 Stocks Rising on Unusual Volume

From a technical perspective, OXBT ripped sharply higher here right above some near-term support at $5.13 and through its 50-day moving average of $5.43 with heavy upside volume. This move is quickly pushing shares of OXBT within range of triggering a big breakout trade. That trade will hit if OXBT manages to take out some near-term overhead resistance levels at $6.44 to $6.93 with high volume.

Traders should now look for long-biased trades in OXBT as long as it's trending above some key near-term support levels at $5.13 and then once it sustains a move or close above those breakout levels with volume that hits near or above 147,898 shares. If that breakout hits soon, then OXBT will set up to re-test or possibly take out its next major overhead resistance levels at $7.60 to $7.90.

Prima Biomed

Prima Biomed (PBMD), a biotechnology company, researches, develops and commercializes licensed medical biotechnology products in Australia. This stock closed up 6.2% to $1.19 in Thursday's trading session.

Thursday's Range: $1.13-$1.25

52-Week Range: $0.82-$4.54

Thursday's Volume: 163,000

Three-Month Average Volume: 175,998

>>Invest Like a Venture Capitalist With These 5 Stocks

From a technical perspective, PBMD spiked sharply higher here right off its 50-day moving average of $1.14 with decent upside volume. This stock recently formed a double bottom chart pattern at $1.04 to $1.02. Following that bottom, shares if PBMD have started to trend back above its 50-day and it's quickly moving within range of triggering a near-term breakout trade. That trade will hit if PBMD manages to take out some near-term overhead resistance levels at $1.23 to $1.34 with high volume.

Traders should now look for long-biased trades in PBMD as long as it's trending above its 50-day at $1.14 or above more near-term support at $1.10 and then once it sustains a move or close above those breakout levels with volume that hits near or above 175,998 shares. If that breakout hits soon, then PBMD will set up to re-test or possibly take out its next major overhead resistance levels at $1.50 to $1.90.

Can-Fite BioPharma

Can-Fite BioPharma (CANF), a biotechnology company, develops drugs for the treatment of cancer and autoimmune inflammatory diseases. This stock closed up 4.4% to $6.07 in Thursday's trading session.

Thursday's Range: $5.74-$6.10

52-Week Range: $3.30-$9.46

Thursday's Volume: 87,000

Three-Month Average Volume: 56,170

>>5 Rocket Stocks to Buy for Repeat Gains in 2014

From a technical perspective, CANF jumped higher here right above some near-term support at $5.68 with above-average volume. This stock recently gapped down sharply from $8.75 to $5.30 with heavy downside volume. Following that move, shares of CANF have started to rebound off that $5.30 low and it's now quickly moving within range of triggering a big breakout trade. That trade will hit if CANF manages to take out some near-term overhead resistance levels at $6.20 to its 50-day moving average of $6.43 with high volume.

Traders should now look for long-biased trades in CANF as long as it's trending above some key near-term support levels at $5.68 or at $5.30 and then once it sustains a move or close above those breakout levels with volume that hits near or above 56,170 shares. If that breakout hits soon, then CANF will set up to re-fill some of its previous gap-down zone that started at $8.75.

ChemoCentryx

ChemoCentryx (CCXI), a biopharmaceutical company, focuses on the discovery, development and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer in the U.S. This stock closed up 5.1% to $6.39 in Thursday's trading session.

Thursday's Range: $6.05-$6.55

52-Week Range: $4.57-$14.96

Thursday's Volume: 1.06 million

Three-Month Average Volume: 477,698

From a technical perspective, CCXI ripped higher here right off some near-term support at $6 with above-average volume. This move briefly pushed shares of CCXI into breakout territory, after the stock flirted with some past overhead resistance at $6.45. Shares of CCXI tagged an intraday high of $6.55 before closing at $6.39. Shares of CCXI are now starting to trend within range of triggering another major breakout trade. That trade will hit if CCXI manages to take out Thursday's high of $6.55 and then its gap-down day high from last September at $6.78 with high volume.

Traders should now look for long-biased trades in CCXI as long as it's trending above Thursday's low of $6.05 or above $6 and then once it sustains a move or close above those breakout levels with volume that hits near or above 477,698 shares. If that breakout triggers soon, then CCXI will set up to re-fill some of its previous gap-down-day zone that started at $8.46.

Geron

Geron (GERN) is a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. This stock closed up 8.2% to $5.23 in Thursday's trading session.

Thursday's Range: $4.81-$5.30

52-Week Range: $0.98-$7.79

Thursday's Volume: 7 million

Three-Month Average Volume: 5.79 million

From a technical perspective, GERN spiked sharply higher here back above its 50-day moving average of $4.93 with strong upside volume flows. This stock recently formed a double bottom chart pattern at $4.50 to $4.55. Following that bottom, shares of GERN have started to spike higher back above its 50-day and it's quickly moving within range of triggering a near-term breakout trade. That trade will hit if GERN can manage to take out some near-term overhead resistance at $5.30 with high volume.

Traders should now look for long-biased trades in GERN as long as it's trending above Thursday's low of $4.81 and then once it sustains a move or close above $5.30 with volume that hits near or above 7 million shares. If that breakout hits soon, then GERN will set up to re-test or possibly take out its next major overhead resistance levels at $6 to $6.92.

To see more stocks that are making notable moves higher, check out the Stocks Under $10 Moving Higher portfolio on Stockpickr.

-- Written by Roberto Pedone in Delafield, Wis.


RELATED LINKS:







Follow Stockpickr on Twitter and become a fan on Facebook.

At the time of publication, author had no positions in stocks mentioned.

Roberto Pedone, based out of Delafield, Wis., is an independent trader who focuses on technical analysis for small- and large-cap stocks, options, futures, commodities and currencies. Roberto studied international business at the Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany. His work has appeared on financial outlets including

CNBC.com and Forbes.com.

You can follow Pedone on Twitter at www.twitter.com/zerosum24 or @zerosum24.